2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn moreSTEM-ing the progression of Parkinson’s
An exciting new clinical trial called STEM-PD is due to start in Sweden and the UK which will focus on stem cell transplantation as a potential treatment for Parkinson’s.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
The 2022 International Linked Clinical Trials meeting
Cure Parkinson’s annually coordinates the International Linked Clinical Trials (iLCT) meeting to rank and prioritise therapies that may have the potential to modify the course of Parkinson’s progression.
2022 Tom Isaacs Award pays tribute to Drs. Michael Okun and Ray Dorsey
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Ray Dorsey, University of Rochester, and Dr Michael Okun, University of Florida, are joint winners of the 2022 Tom Isaacs Award.
Phase 1 trial results of new GDNF delivery mechanism
The results of a recent clinical trial testing a new way of delivering the nerve growth factor, GDNF, into the brains of people with Parkinson’s demonstrate that it is safe and well tolerated. Glial cell-line derived neurotrophic factor, or GDNF as it is more commonly…